A Scientific Reports study developed a pattern neural network that integrates total antioxidant status with clinical and ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...

Just because it’s cold doesn’t mean ticks are no longer a problem. The creature recently named pest of the year by the ...

The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

A highly accurate AI model improves prediabetes prediction by integrating antioxidant status with standard risk factors.

Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults ...

The approval was supported by data from phase 3 STEER study, which enrolled patients with SMA who were treatment-naive and able to sit but never able to walk independently.

The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read ...

The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

Operational real-world data analyzed from patients prescribed ZYNTEGLO™ and LYFGENIA™Data demonstrates the value proposition of one-time, durable gene therapy for the treatment of sickle cell disease ...